Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | ACHE | P22303 | 4/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338041 | 1.00 | CA1 (0.47) | CA1CA2ACHEEPHX2MTNR1A | |
| SCHEMBL4101120 | 1.00 | CA1 (0.47) | CA1CA2ACHEEPHX2MTNR1A | |
| SCHEMBL464262 | 0.95 | MTNR1A (0.50) | CA1CA2ACHEEPHX2MTNR1A | |
| SCHEMBL29878515 | 0.89 | EPHX2 (0.50) | CA1CA2EPHX2DRD2AAK1 | |
| SCHEMBL1545211 | 0.89 | EPHX2 (0.50) | CA1CA2EPHX2DRD2AAK1 | |
| SCHEMBL1545000 | 0.89 | EPHX2 (0.50) | CA1CA2EPHX2DRD2AAK1 | |
| SCHEMBL1545004 | 0.89 | EPHX2 (0.50) | CA1CA2EPHX2DRD2AAK1 | |
| SCHEMBL13262741 | 0.86 | CA1 (0.48) | CA1CA2ACHEEPHX2MTNR1A | |
| SCHEMBL7399411 | 0.86 | CA1 (0.64) | CA1CA2ACHEEPHX2MTNR1A | |
| SCHEMBL13263584 | 0.85 | CA1 (0.47) | CA1CA2ACHEEPHX2MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106715395-B | 6-amino-5, 6, 7, 8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives as TAAR modulators | 豪夫迈·罗氏有限公司 | 2020-05-12 | — | — | CN | disclosed |
| EP-3174853-B1 | 6-AMINO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL OR 3-AMINOCHROMAN-7-YL DERIVATIVES AS TAAR MODULATORS | HOFFMANN LA ROCHE (CH) | 2018-12-12 | — | — | EP | disclosed |
| US-9957261-B2 | 6-amino-5,6,7,8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2018-05-01 | — | — | US | disclosed |
| EP-3174853-A1 | 6-AMINO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL OR 3-AMINOCHROMAN-7-YL DERIVATIVES AS TAAR MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-06-07 | — | — | EP | disclosed |
| US-20170137416-A1 | 6-AMINO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL OR 3-AMINOCHROMAN-7-YL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-05-18 | — | — | US | disclosed |
| WO-2016016162-A1 | 6-AMINO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL OR 3-AMINOCHROMAN-7-YL DERIVATIVES AS TAAR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-02-04 | — | — | WO | disclosed |
| US-8969552-B2 | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-03-03 | — | — | US | disclosed |
| EP-1812416-B1 | ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2013-08-21 | — | — | EP | disclosed |
| US-20090012074-A1 | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the Dopamine D3 receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2009-01-08 | — | — | US | disclosed |
| EP-1812416-A1 | ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MADULATION OF THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006040178-A9 | ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MADULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2007-04-19 | — | — | WO | disclosed |
| WO-2006040178-A1 | ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MADULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO.KG (DE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137416-A1 | 6-AMINO-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL OR 3-AMINOCHROMAN-7-YL DERIVATIVES | TAAR5, TAAR1, HTR1A | CA1 1568/4885CA2 3624/4885ACHE 1025/4885 |
| US-20090012074-A1 | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the Dopamine D3 receptor | ADRB3, SLC6A3, NR3C2 | CA1 3066/4885CA2 1625/4885ACHE 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.